Hi to all,
Does anyone have statistics on the burden of disease for MS? That is, what is the dollar cost to society for someone with MS -- lost wages, medical care, etc.
MS burden of disease
-
IHaveMS-com
- Family Elder
- Posts: 214
- Joined: Tue Jun 07, 2005 2:00 pm
- Contact:
MS burden of disease
Best regards, Tim
In 2001, my family helped fund the startup of Opexa. My father served on the Board of Directors of PharmaFrontiers, now Opexa Therapeutics, until the company completed a successful 23-million dollar financing round.
In 2001, my family helped fund the startup of Opexa. My father served on the Board of Directors of PharmaFrontiers, now Opexa Therapeutics, until the company completed a successful 23-million dollar financing round.
-
TwistedHelix
- Family Elder
- Posts: 602
- Joined: Fri Mar 25, 2005 3:00 pm
- Location: Northamptonshire, England.
Hi Tim,
The financial cost of a disease like MS is composed of so many variables that it must be nearly impossible to work out accurately, but this link may give you some idea. Bear in mind that the statistics are from 1994:
http://msj.sagepub.com/cgi/content/abstract/4/5/419
They put the annual cost to the U.S. at $6.8 billion, which reinforces the point I've made before: that if the answer to MS lies in something which is non-patentable, it is surely in a nation's best interests for the government to fund and develop those projects,
The financial cost of a disease like MS is composed of so many variables that it must be nearly impossible to work out accurately, but this link may give you some idea. Bear in mind that the statistics are from 1994:
http://msj.sagepub.com/cgi/content/abstract/4/5/419
They put the annual cost to the U.S. at $6.8 billion, which reinforces the point I've made before: that if the answer to MS lies in something which is non-patentable, it is surely in a nation's best interests for the government to fund and develop those projects,
Dom
-
IHaveMS-com
- Family Elder
- Posts: 214
- Joined: Tue Jun 07, 2005 2:00 pm
- Contact:
Hi Dom and thanks,
The key words for the link you posted got me to some other interesting places. Since you are from the UK, this is a study for the UK and a 35-page accompanying PDF.
http://swopec.hhs.se/hastef/papers/hastef0398.pdf
http://ideas.repec.org/p/hhs/hastef/0398.html
Costs and Quality of Life in Multiple Sclerosis. A Cross-Sectional Observational Study in the UK
Abstract: We performed a cross-sectional, "bottom-up" observational study of resource consumption and quality of life of patients with multiple sclerosis (MS) in the United Kingdom. Three centers participated in the study. Patients received a questionnaire either by mail or during a clinic visit, and a total of 619 patients returned the questionnaire (the answer rate being around 70%). Patients provided information on all resource consumption, medical and non-medical, work absence and informal care related to their MS. Disease scores (Expanded Disability Status Scale, EDSS) were available for a majority of patients from the study centers, and were assigned using a matrix of disease (mobility) descriptions and EDSS scores. Mean total cost per patient and year was 16’717 £. When this cost is extrapolated to an estimated patient population in the UK of 80’000, total costs to society are estimated at 1.34 billion £. Direct costs represented 28%, informal care accounted for 26% and indirect costs amounted to 46%. Of the direct costs, an estimated £ per patient or % of total costs are paid for by the NHS. Intangible costs were estimated at 5000 £ per patient and year.
The mean age of the cohort was 44 years (disease onset 34), the mean utility measured with EQ-5D was 0.487 (0.919 to –0.594), and the mean EDSS score 5.1 (1.0 to 9.5). All costs (direct, informal care, indirect) increased with increasing EDSS scores, while utilities decreased.
Here are 2 PDFs relative to the issue.
http://swopec.hhs.se/hastef/papers/hastef0594.pdf
COSTS AND QUALITY OF LIFE IN MULTIPLE SCLEROSIS A CROSS-SECTIONAL STUDY IN THE USA
http://www.ncchta.org/fullmono/mon610.pdf
A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models 2002
This is a more recent study about the US.
http://neurology.org/cgi/content/abstra ... 696?ck=nck
http://www.ncbi.nlm.nih.gov/sites/entre ... t=Citation
NEUROLOGY 2006;66:1696-1702
© 2006 American Academy of Neurology
Costs and quality of life in multiple sclerosis
A cross-sectional study in the United States
Gisela Kobelt, PhD, Jenny Berg, MSc, Deborah Atherly, RPh, MPH and Olympia Hadjimichael, RPh, MPH
From the Karolinska Institute (G.K.), Stockholm, Sweden, and European Health Economics, France; Stockholm Health Economics (J.B.), Sweden; University of Washington (D.A.); and School of Medicine (O.H.), Yale University, New Haven, CT.
Address correspondence and reprint requests to Dr. Gisela Kobelt, European Health Economics, 492, Chemin des Laurens, F-06530 Speracedes, France; e-mail: gisela.kobelt@he-europe.com
Objective: To estimate current costs and quality of life (utility) of patients treated with disease modifying drugs (DMDs) in the United States, and to investigate the effect of disease severity on costs and utility.
Methods: Data on demographics, disease information, resource utilization (including work capacity), and utility were collected directly from patients in a cross-sectional postal survey. Patients were selected randomly among participants in the North American Committee on Multiple Sclerosis Patient Registry (NARCOMS) receiving DMDs. Mean annual costs per patient (2004 USD) and mean utilities for the sample and for different levels of functional disability are estimated from the societal perspective.
Results: The target answer rate of 50% was reached and 1,909 patients were included in the analysis. The mean age was 49 years and time since diagnosis was 13 years. A total of 10.5% of patients had primary progressive, 47.6% relapsing-remitting, and 33.3% secondary progressive disease. A total of 28.8% of patients indicated to have experienced a relapse during the past 3 months. Total average costs are estimated at $47,215 per patient and year. Of these, 53% were for direct medical and non-medical costs, 37% for production losses, and 10% for informal care. Mean utility in the sample was 0.698.
Conclusions: Consistent with other studies, costs and utilities were significantly correlated with functional capacity. The proportion of costs represented by disease modifying drugs is considerably lower than estimated in other studies, as all costs related to the disease are included.
Citation -- OBJECTIVE: To estimate current costs and quality of life (utility) of patients treated with disease modifying drugs (DMDs) in the United States, and to investigate the effect of disease severity on costs and utility. METHODS: Data on demographics, disease information, resource utilization (including work capacity), and utility were collected directly from patients in a cross-sectional postal survey. Patients were selected randomly among participants in the North American Committee on Multiple Sclerosis Patient Registry (NARCOMS) receiving DMDs. Mean annual costs per patient (2004 USD) and mean utilities for the sample and for different levels of functional disability are estimated from the societal perspective. RESULTS: The target answer rate of 50% was reached and 1,909 patients were included in the analysis. The mean age was 49 years and time since diagnosis was 13 years. A total of 10.5% of patients had primary progressive, 47.6% relapsing-remitting, and 33.3% secondary progressive disease. A total of 28.8% of patients indicated to have experienced a relapse during the past 3 months. Total average costs are estimated at 47,215 dollars per patient and year. Of these, 53% were for direct medical and non-medical costs, 37% for production losses, and 10% for informal care. Mean utility in the sample was 0.698. CONCLUSIONS: Consistent with other studies, costs and utilities were significantly correlated with functional capacity. The proportion of costs represented by disease modifying drugs is considerably lower than estimated in other studies, as all costs related to the disease are included.
The key words for the link you posted got me to some other interesting places. Since you are from the UK, this is a study for the UK and a 35-page accompanying PDF.
http://swopec.hhs.se/hastef/papers/hastef0398.pdf
http://ideas.repec.org/p/hhs/hastef/0398.html
Costs and Quality of Life in Multiple Sclerosis. A Cross-Sectional Observational Study in the UK
Abstract: We performed a cross-sectional, "bottom-up" observational study of resource consumption and quality of life of patients with multiple sclerosis (MS) in the United Kingdom. Three centers participated in the study. Patients received a questionnaire either by mail or during a clinic visit, and a total of 619 patients returned the questionnaire (the answer rate being around 70%). Patients provided information on all resource consumption, medical and non-medical, work absence and informal care related to their MS. Disease scores (Expanded Disability Status Scale, EDSS) were available for a majority of patients from the study centers, and were assigned using a matrix of disease (mobility) descriptions and EDSS scores. Mean total cost per patient and year was 16’717 £. When this cost is extrapolated to an estimated patient population in the UK of 80’000, total costs to society are estimated at 1.34 billion £. Direct costs represented 28%, informal care accounted for 26% and indirect costs amounted to 46%. Of the direct costs, an estimated £ per patient or % of total costs are paid for by the NHS. Intangible costs were estimated at 5000 £ per patient and year.
The mean age of the cohort was 44 years (disease onset 34), the mean utility measured with EQ-5D was 0.487 (0.919 to –0.594), and the mean EDSS score 5.1 (1.0 to 9.5). All costs (direct, informal care, indirect) increased with increasing EDSS scores, while utilities decreased.
Here are 2 PDFs relative to the issue.
http://swopec.hhs.se/hastef/papers/hastef0594.pdf
COSTS AND QUALITY OF LIFE IN MULTIPLE SCLEROSIS A CROSS-SECTIONAL STUDY IN THE USA
http://www.ncchta.org/fullmono/mon610.pdf
A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models 2002
This is a more recent study about the US.
http://neurology.org/cgi/content/abstra ... 696?ck=nck
http://www.ncbi.nlm.nih.gov/sites/entre ... t=Citation
NEUROLOGY 2006;66:1696-1702
© 2006 American Academy of Neurology
Costs and quality of life in multiple sclerosis
A cross-sectional study in the United States
Gisela Kobelt, PhD, Jenny Berg, MSc, Deborah Atherly, RPh, MPH and Olympia Hadjimichael, RPh, MPH
From the Karolinska Institute (G.K.), Stockholm, Sweden, and European Health Economics, France; Stockholm Health Economics (J.B.), Sweden; University of Washington (D.A.); and School of Medicine (O.H.), Yale University, New Haven, CT.
Address correspondence and reprint requests to Dr. Gisela Kobelt, European Health Economics, 492, Chemin des Laurens, F-06530 Speracedes, France; e-mail: gisela.kobelt@he-europe.com
Objective: To estimate current costs and quality of life (utility) of patients treated with disease modifying drugs (DMDs) in the United States, and to investigate the effect of disease severity on costs and utility.
Methods: Data on demographics, disease information, resource utilization (including work capacity), and utility were collected directly from patients in a cross-sectional postal survey. Patients were selected randomly among participants in the North American Committee on Multiple Sclerosis Patient Registry (NARCOMS) receiving DMDs. Mean annual costs per patient (2004 USD) and mean utilities for the sample and for different levels of functional disability are estimated from the societal perspective.
Results: The target answer rate of 50% was reached and 1,909 patients were included in the analysis. The mean age was 49 years and time since diagnosis was 13 years. A total of 10.5% of patients had primary progressive, 47.6% relapsing-remitting, and 33.3% secondary progressive disease. A total of 28.8% of patients indicated to have experienced a relapse during the past 3 months. Total average costs are estimated at $47,215 per patient and year. Of these, 53% were for direct medical and non-medical costs, 37% for production losses, and 10% for informal care. Mean utility in the sample was 0.698.
Conclusions: Consistent with other studies, costs and utilities were significantly correlated with functional capacity. The proportion of costs represented by disease modifying drugs is considerably lower than estimated in other studies, as all costs related to the disease are included.
Citation -- OBJECTIVE: To estimate current costs and quality of life (utility) of patients treated with disease modifying drugs (DMDs) in the United States, and to investigate the effect of disease severity on costs and utility. METHODS: Data on demographics, disease information, resource utilization (including work capacity), and utility were collected directly from patients in a cross-sectional postal survey. Patients were selected randomly among participants in the North American Committee on Multiple Sclerosis Patient Registry (NARCOMS) receiving DMDs. Mean annual costs per patient (2004 USD) and mean utilities for the sample and for different levels of functional disability are estimated from the societal perspective. RESULTS: The target answer rate of 50% was reached and 1,909 patients were included in the analysis. The mean age was 49 years and time since diagnosis was 13 years. A total of 10.5% of patients had primary progressive, 47.6% relapsing-remitting, and 33.3% secondary progressive disease. A total of 28.8% of patients indicated to have experienced a relapse during the past 3 months. Total average costs are estimated at 47,215 dollars per patient and year. Of these, 53% were for direct medical and non-medical costs, 37% for production losses, and 10% for informal care. Mean utility in the sample was 0.698. CONCLUSIONS: Consistent with other studies, costs and utilities were significantly correlated with functional capacity. The proportion of costs represented by disease modifying drugs is considerably lower than estimated in other studies, as all costs related to the disease are included.
Best regards, Tim
In 2001, my family helped fund the startup of Opexa. My father served on the Board of Directors of PharmaFrontiers, now Opexa Therapeutics, until the company completed a successful 23-million dollar financing round.
In 2001, my family helped fund the startup of Opexa. My father served on the Board of Directors of PharmaFrontiers, now Opexa Therapeutics, until the company completed a successful 23-million dollar financing round.